Symbol
GILD
ISIN
US3755581036
Börse
NASDAQ
Sektor
Health Care
Marktkapitalisierung
79.3861 Mrd. US
Branche
Biotechnology
Dividendenrendite
4.36 %
Ausschüttungsquote
43.87 %
KGV
62.89
KUV (TTM)
3.41
KGVe
9.71
Kursziel
72.46 USD
Symbol
GILD
ISIN
US3755581036
Börse
NASDAQ
Marktkapitalisierung
79.3861 Mrd. USD
Sektor
Health Care
Branche
Biotechnology
Dividendenrendite
4.36 %
Ausschüttungsquote
43.87 %
KGV
62.89
KUV (TTM)
3.41
KGVe
9.71
Kursziel
72.46 USD
Live-Chart (verzögert)
Firmenbeschreibung
Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases. It also provides Yescarta, a chimeric antigen receptor T cell therapy for adult patients with relapsed or refractory large B-cell lymphoma; Zydelig, a kinase inhibitor; Letairis, an oral formulation of an endothelin receptor antagonist for pulmonary arterial hypertension; Ranexa, a tablet to treat chronic angina; and AmBisome, an antifungal agent to treat serious invasive fungal infections. In addition, the company offers its products under the name Cayston, Emtriva, Hepsera, Sovaldi, and Tybost. Further, it develops product candidates for the treatment of viral diseases, inflammatory and fibrotic diseases, and oncology. The company markets its products through its commercial teams; and in conjunction with third-party distributors and corporate partners. Gilead Sciences, Inc. has collaboration agreements with Bristol-Myers Squibb Company; Janssen Sciences Ireland UC; Japan Tobacco Inc.; Galapagos NV; Second Genome; Gadeta; Carna Biosciences Inc.; Nurix Therapeutics, Inc.; Humanigen, Inc.; Kiniksa Pharmaceuticals, Ltd.; Kyverna Therapeutics, Inc.; Glympse Bio, Inc.; Renown Institute for Health Innovation; Goldfinch Bio, Inc.; Insitro, Inc.; Novo Nordisk A/S; Yuhan Corporation; Kite Pharma, Inc.; oNKo-innate Pty. Ltd.; Roche Holding AG; and Vir Biotechnology, Inc. The company has partnership with Arcus Biosciences, Inc. to co-develop and co-commercialize next-generation cancer immunotherapies. Gilead Sciences, Inc. was founded in 1987 and is headquartered in Foster City, California.
Gilead Sciences, Inc Fundamentaldaten
Jahre und Quartale beziehen sich jeweils auf das Geschäftsjahr des Unternehmens. (Das Geschäftsjahr kann ggf. vom Kalenderjahr abweichen.)
Das Geschäftsjahr von Gilead Sciences, Inc endet im Dezember.
Gewinn pro Jahr & Quartal (Net Income) in Mrd. USD
| Q1 Jan-Mrz |
Q2 Apr-Jun |
Q3 Jul-Sep |
Q4 Okt-Dez |
Jahr Jan-Dez |
|
|---|---|---|---|---|---|
| 2021 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 |
| 2020 | 1.551 | -3.339 | 0.360 | 0.000 | -1.428 |
| 2019 | 1.975 | 1.880 | -1.165 | 2.696 | 5.386 |
| 2018 | 1.538 | 1.817 | 2.097 | 0.003 | 5.455 |
| 2017 | 2.702 | 3.073 | 2.718 | -3.865 | 4.628 |
| 2016 | 3.566 | 3.497 | 3.330 | 3.108 | 13.501 |
| 2015 | 4.333 | 4.492 | 4.600 | 4.683 | 18.108 |
| 2014 | 2.227 | 3.656 | 2.731 | 3.487 | 12.101 |
| 2013 | 0.722 | 0.773 | 0.789 | 0.791 | 3.075 |
| 2012 | 0.438 | 0.706 | 0.676 | 0.772 | 2.592 |
| 2011 | 0.651 | 0.746 | 0.741 | 0.665 | 2.804 |
| 2010 | 0.855 | 0.712 | 0.705 | 0.629 | 2.901 |
Gewinn je Aktie (EPS) pro Jahr & Quartal (non-GAAP)
| Q1 Jan-Mrz |
Q2 Apr-Jun |
Q3 Jul-Sep |
Q4 Okt-Dez |
Jahr Jan-Dez |
|
|---|---|---|---|---|---|
| 2021 | 0 | 0 | 0 | 0 | 0 |
| 2020 | 1.68 | 1.11 | 2.11 | 0 | 4.9 |
| 2019 | 1.76 | 1.82 | 1.75 | 1.3 | 6.63 |
| 2018 | 1.48 | 1.91 | 1.84 | 1.44 | 6.67 |
| 2017 | 2.23 | 2.56 | 2.27 | 1.78 | 8.84 |
| 2016 | 3.03 | 3.08 | 2.75 | 2.7 | 11.56 |
| 2015 | 2.94 | 3.15 | 3.22 | 3.32 | 12.63 |
| 2014 | 1.48 | 2.36 | 1.84 | 2.43 | 8.11 |
| 2013 | 0.48 | 0.5 | 0.52 | 0.55 | 2.05 |
| 2012 | 0.46 | 0.5 | 0.5 | 0.5 | 1.96 |
| 2011 | 0.44 | 0.5 | 0.51 | 0.49 | 1.94 |
| 2010 | 0.5 | 0.43 | 0.45 | 0.48 | 1.86 |
Umsatz pro Jahr & Quartal in Mrd. USD
| Q1 Jan-Mrz |
Q2 Apr-Jun |
Q3 Jul-Sep |
Q4 Okt-Dez |
Jahr Jan-Dez |
|
|---|---|---|---|---|---|
| 2021 | 0 | 0 | 0 | 0 | 0 |
| 2020 | 5.548 | 5.143 | 6.577 | 0 | 17.268 |
| 2019 | 5.281 | 5.685 | 5.604 | 5.879 | 22.449 |
| 2018 | 5.088 | 5.648 | 5.596 | 5.795 | 22.127 |
| 2017 | 6.505 | 7.141 | 6.512 | 5.949 | 26.107 |
| 2016 | 7.794 | 7.776 | 7.5 | 7.32 | 30.39 |
| 2015 | 7.594 | 8.244 | 8.295 | 8.506 | 32.639 |
| 2014 | 4.99896 | 6.53494 | 6.04183 | 7.31427 | 24.89 |
| 2013 | 2.53164 | 2.76739 | 2.78283 | 3.11983 | 11.2017 |
| 2012 | 2.28245 | 2.40519 | 2.4266 | 2.58828 | 9.70252 |
| 2011 | 1.92609 | 2.13725 | 2.12166 | 2.20038 | 8.38538 |
| 2010 | 2.08585 | 1.92722 | 1.93766 | 1.99869 | 7.94942 |
Umsatz je Aktie pro Jahr & Quartal
| Q1 Jan-Mrz |
Q2 Apr-Jun |
Q3 Jul-Sep |
Q4 Okt-Dez |
Jahr Jan-Dez |
|
|---|---|---|---|---|---|
| 2021 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| 2020 | 4.37 | 4.10 | 5.22 | 0.00 | 28.17 |
| 2019 | 4.12 | 4.45 | 4.42 | 4.60 | 17.58 |
| 2018 | 3.85 | 4.32 | 4.28 | 4.43 | 16.92 |
| 2017 | 4.93 | 5.42 | 4.94 | 4.51 | 19.79 |
| 2016 | 5.52 | 5.74 | 5.60 | 5.39 | 22.38 |
| 2015 | 4.84 | 5.35 | 5.52 | 5.59 | 21.46 |
| 2014 | 2.98 | 3.93 | 3.69 | 4.44 | 15.11 |
| 2013 | 1.52 | 1.63 | 1.64 | 1.84 | 6.61 |
| 2012 | 1.47 | 1.54 | 1.53 | 1.64 | 6.13 |
| 2011 | 1.19 | 1.33 | 1.36 | 1.39 | 5.31 |
| 2010 | 1.12 | 1.07 | 1.14 | 1.14 | 4.55 |
Gewinn-Wachstum in Prozent
| Q1 Jan-Mrz |
Q2 Apr-Jun |
Q3 Jul-Sep |
Q4 Okt-Dez |
Jahr Jan-Dez |
|
|---|---|---|---|---|---|
| 2021 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| 2020 | -42.47 | -315.28 | 0.00 | -100.00 | -126.51 |
| 2019 | 65733.33 | -4.81 | -161.97 | 0.00 | -1.26 |
| 2018 | 0.00 | 18.14 | 15.41 | -99.86 | 17.87 |
| 2017 | -13.06 | 13.73 | -11.55 | -242.20 | -65.72 |
| 2016 | -23.85 | -1.93 | -4.78 | -6.67 | -25.44 |
| 2015 | 24.27 | 3.67 | 2.40 | 1.80 | 49.64 |
| 2014 | 181.45 | 64.12 | -25.29 | 27.66 | 293.55 |
| 2013 | -6.51 | 6.98 | 2.07 | 0.36 | 18.65 |
| 2012 | -34.22 | 61.38 | -4.33 | 14.35 | -7.56 |
| 2011 | 3.45 | 14.60 | -0.68 | -10.25 | -3.36 |
| 2010 | 6.57 | -16.71 | -1.01 | -10.71 | 10.07 |
Umsatz-Wachstum in Prozent
| Q1 Jan-Mrz |
Q2 Apr-Jun |
Q3 Jul-Sep |
Q4 Okt-Dez |
Jahr Jan-Dez |
|
|---|---|---|---|---|---|
| 2021 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| 2020 | -5.63 | -7.30 | 27.88 | 0.00 | 0.00 |
| 2019 | -8.87 | 7.65 | -1.42 | 4.91 | 1.46 |
| 2018 | -14.47 | 11.01 | -0.92 | 3.56 | -15.24 |
| 2017 | -11.13 | 9.78 | -8.81 | -8.65 | -14.09 |
| 2016 | -8.37 | -0.23 | -3.55 | -2.40 | -6.89 |
| 2015 | 3.82 | 8.56 | 0.62 | 2.54 | 31.13 |
| 2014 | 60.23 | 30.73 | -7.55 | 21.06 | 122.20 |
| 2013 | -2.19 | 9.31 | 0.56 | 12.11 | 15.45 |
| 2012 | 3.73 | 5.38 | 0.89 | 6.66 | 15.71 |
| 2011 | -3.63 | 10.96 | -0.73 | 3.71 | 5.48 |
| 2010 | 2.63 | -7.60 | 0.54 | 3.15 | 13.38 |
Gilead Sciences, Inc Fundamentaldaten
Gewinn pro Jahr & Quartal (Net Income)
| Q1 Jan-Mrz |
Q2 Apr-Jun |
Q3 Jul-Sep |
Q4 Okt-Dez |
Jahr Jan-Dez |
|
|---|---|---|---|---|---|
| 2021 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 |
| 2020 | 1.551 | -3.339 | 0.360 | 0.000 | -1.428 |
| 2019 | 1.975 | 1.880 | -1.165 | 2.696 | 5.386 |
| 2018 | 1.538 | 1.817 | 2.097 | 0.003 | 5.455 |
| 2017 | 2.702 | 3.073 | 2.718 | -3.865 | 4.628 |
| 2016 | 3.566 | 3.497 | 3.330 | 3.108 | 13.501 |
| 2015 | 4.333 | 4.492 | 4.600 | 4.683 | 18.108 |
| 2014 | 2.227 | 3.656 | 2.731 | 3.487 | 12.101 |
| 2013 | 0.722 | 0.773 | 0.789 | 0.791 | 3.075 |
| 2012 | 0.438 | 0.706 | 0.676 | 0.772 | 2.592 |
| 2011 | 0.651 | 0.746 | 0.741 | 0.665 | 2.804 |
| 2010 | 0.855 | 0.712 | 0.705 | 0.629 | 2.901 |
Gewinn je Aktie (EPS) pro Jahr & Quartal (non-GAAP)
| Q1 Jan-Mrz |
Q2 Apr-Jun |
Q3 Jul-Sep |
Q4 Okt-Dez |
Jahr Jan-Dez |
|
|---|---|---|---|---|---|
| 2021 | 0 | 0 | 0 | 0 | 0 |
| 2020 | 1.68 | 1.11 | 2.11 | 0 | 4.9 |
| 2019 | 1.76 | 1.82 | 1.75 | 1.3 | 6.63 |
| 2018 | 1.48 | 1.91 | 1.84 | 1.44 | 6.67 |
| 2017 | 2.23 | 2.56 | 2.27 | 1.78 | 8.84 |
| 2016 | 3.03 | 3.08 | 2.75 | 2.7 | 11.56 |
| 2015 | 2.94 | 3.15 | 3.22 | 3.32 | 12.63 |
| 2014 | 1.48 | 2.36 | 1.84 | 2.43 | 8.11 |
| 2013 | 0.48 | 0.5 | 0.52 | 0.55 | 2.05 |
| 2012 | 0.46 | 0.5 | 0.5 | 0.5 | 1.96 |
| 2011 | 0.44 | 0.5 | 0.51 | 0.49 | 1.94 |
| 2010 | 0.5 | 0.43 | 0.45 | 0.48 | 1.86 |
Umsatz pro Jahr & Quartal
| Q1 Jan-Mrz |
Q2 Apr-Jun |
Q3 Jul-Sep |
Q4 Okt-Dez |
Jahr Jan-Dez |
|
|---|---|---|---|---|---|
| 2021 | 0 | 0 | 0 | 0 | 0 |
| 2020 | 5.548 | 5.143 | 6.577 | 0 | 17.268 |
| 2019 | 5.281 | 5.685 | 5.604 | 5.879 | 22.449 |
| 2018 | 5.088 | 5.648 | 5.596 | 5.795 | 22.127 |
| 2017 | 6.505 | 7.141 | 6.512 | 5.949 | 26.107 |
| 2016 | 7.794 | 7.776 | 7.5 | 7.32 | 30.39 |
| 2015 | 7.594 | 8.244 | 8.295 | 8.506 | 32.639 |
| 2014 | 4.99896 | 6.53494 | 6.04183 | 7.31427 | 24.89 |
| 2013 | 2.53164 | 2.76739 | 2.78283 | 3.11983 | 11.2017 |
| 2012 | 2.28245 | 2.40519 | 2.4266 | 2.58828 | 9.70252 |
| 2011 | 1.92609 | 2.13725 | 2.12166 | 2.20038 | 8.38538 |
| 2010 | 2.08585 | 1.92722 | 1.93766 | 1.99869 | 7.94942 |
Umsatz je Aktie pro Jahr & Quartal
| Q1 Jan-Mrz |
Q2 Apr-Jun |
Q3 Jul-Sep |
Q4 Okt-Dez |
Jahr Jan-Dez |
|
|---|---|---|---|---|---|
| 2021 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| 2020 | 4.37 | 4.10 | 5.22 | 0.00 | 28.17 |
| 2019 | 4.12 | 4.45 | 4.42 | 4.60 | 17.58 |
| 2018 | 3.85 | 4.32 | 4.28 | 4.43 | 16.92 |
| 2017 | 4.93 | 5.42 | 4.94 | 4.51 | 19.79 |
| 2016 | 5.52 | 5.74 | 5.60 | 5.39 | 22.38 |
| 2015 | 4.84 | 5.35 | 5.52 | 5.59 | 21.46 |
| 2014 | 2.98 | 3.93 | 3.69 | 4.44 | 15.11 |
| 2013 | 1.52 | 1.63 | 1.64 | 1.84 | 6.61 |
| 2012 | 1.47 | 1.54 | 1.53 | 1.64 | 6.13 |
| 2011 | 1.19 | 1.33 | 1.36 | 1.39 | 5.31 |
| 2010 | 1.12 | 1.07 | 1.14 | 1.14 | 4.55 |
Gewinn-Wachstum in Prozent
| Q1 Jan-Mrz |
Q2 Apr-Jun |
Q3 Jul-Sep |
Q4 Okt-Dez |
Jahr Jan-Dez |
|
|---|---|---|---|---|---|
| 2021 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| 2020 | -42.47 | -315.28 | 0.00 | -100.00 | -126.51 |
| 2019 | 65733.33 | -4.81 | -161.97 | 0.00 | -1.26 |
| 2018 | 0.00 | 18.14 | 15.41 | -99.86 | 17.87 |
| 2017 | -13.06 | 13.73 | -11.55 | -242.20 | -65.72 |
| 2016 | -23.85 | -1.93 | -4.78 | -6.67 | -25.44 |
| 2015 | 24.27 | 3.67 | 2.40 | 1.80 | 49.64 |
| 2014 | 181.45 | 64.12 | -25.29 | 27.66 | 293.55 |
| 2013 | -6.51 | 6.98 | 2.07 | 0.36 | 18.65 |
| 2012 | -34.22 | 61.38 | -4.33 | 14.35 | -7.56 |
| 2011 | 3.45 | 14.60 | -0.68 | -10.25 | -3.36 |
| 2010 | 6.57 | -16.71 | -1.01 | -10.71 | 10.07 |
Umsatz-Wachstum in Prozent
| Q1 Jan-Mrz |
Q2 Apr-Jun |
Q3 Jul-Sep |
Q4 Okt-Dez |
Jahr Jan-Dez |
|
|---|---|---|---|---|---|
| 2021 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| 2020 | -5.63 | -7.30 | 27.88 | 0.00 | 0.00 |
| 2019 | -8.87 | 7.65 | -1.42 | 4.91 | 1.46 |
| 2018 | -14.47 | 11.01 | -0.92 | 3.56 | -15.24 |
| 2017 | -11.13 | 9.78 | -8.81 | -8.65 | -14.09 |
| 2016 | -8.37 | -0.23 | -3.55 | -2.40 | -6.89 |
| 2015 | 3.82 | 8.56 | 0.62 | 2.54 | 31.13 |
| 2014 | 60.23 | 30.73 | -7.55 | 21.06 | 122.20 |
| 2013 | -2.19 | 9.31 | 0.56 | 12.11 | 15.45 |
| 2012 | 3.73 | 5.38 | 0.89 | 6.66 | 15.71 |
| 2011 | -3.63 | 10.96 | -0.73 | 3.71 | 5.48 |
| 2010 | 2.63 | -7.60 | 0.54 | 3.15 | 13.38 |
Gilead Sciences, Inc Dividenden-Entwicklung
| Ex-Tag | Record Date | Zahltag | Dividende |
|---|---|---|---|
| 2020-12-14 | 2020-12-15 | 2020-12-30 | 0.68 |
| 2020-09-14 | 2020-09-15 | 2020-09-29 | 0.68 |
| 2020-06-11 | 2020-06-12 | 2020-06-29 | 0.68 |
| 2020-03-12 | 2020-03-13 | 2020-03-30 | 0.68 |
| 2019-12-12 | 2019-12-13 | 2019-12-30 | 0.63 |
| 2019-09-12 | 2019-09-13 | 2019-09-27 | 0.63 |
| 2019-06-13 | 2019-06-14 | 2019-06-27 | 0.63 |
| 2019-03-14 | 2019-03-15 | 2019-03-28 | 0.63 |
| 2018-12-13 | 2018-12-14 | 2018-12-28 | 0.57 |
| 2018-09-13 | 2018-09-14 | 2018-09-27 | 0.57 |
| 2018-06-14 | 2018-06-15 | 2018-06-28 | 0.57 |
| 2018-03-15 | 2018-03-16 | 2018-03-29 | 0.57 |
| 2017-12-14 | 2017-12-15 | 2017-12-28 | 0.52 |
| 2017-09-14 | 2017-09-15 | 2017-09-28 | 0.52 |
| 2017-06-14 | 2017-06-16 | 2017-06-29 | 0.52 |
| 2017-03-14 | 2017-03-16 | 2017-03-30 | 0.52 |
| 2016-12-13 | 2016-12-15 | 2016-12-29 | 0.47 |
| 2016-09-14 | 2016-09-16 | 2016-09-29 | 0.47 |
| 2016-06-14 | 2016-06-16 | 2016-06-29 | 0.47 |
| 2016-03-14 | 2016-03-16 | 2016-03-30 | 0.43 |
Hinterlasse einen Kommentar